Currents of disruption: gene therapy offers rare hope

22/10/2018

Download


 
Our understanding of the genetic causes of disease has reached a critical stage, putting us on the cusp of being able to develop functional cures for a large number of rare genetic disorders, says Global Life Sciences Co-Portfolio Manager, Andy Acker.
 
Key takeaways:
  • Gene therapy has the potential to provide “one and done” treatments that can correct genetic defects that cause life-threatening diseases.
  • Biopharmaceutical companies are working on treatments for the more than 7000 known genetic disorders, including haemophilia, muscular dystrophy and spinal muscular atrophy – the biggest genetic cause of infant death.
  • As investors, we recognise the importance of looking not only at large, public companies working on gene therapies, but also at the smaller innovators that have the potential to be disruptive.

 Video recorded on 1 September 2018.

 

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.

Anything non-factual in nature is an opinion of the author(s), and opinions are meant as an illustration of broader themes, are not an indication of trading intent, and are subject to change at any time due to changes in market or economic conditions. It is not intended to indicate or imply that any illustration/example mentioned is now or was ever held in any portfolio. No forecasts can be guaranteed and there is no guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its us.


Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Global Life Sciences Fund

Key investment risks to be considered before investing.

  • The Fund may invest in any one or a combination of the following instruments:
    • futures, options and swaps and other financial derivative instruments (“FDI”) for investment purposes, up to 10% of the net asset value ("NAV") of the Fund. Given the leverage effect of FDI, such investments may result in substantial loss (as much as 100% of the NAV of the relevant Fund);
    • debt securities rated below investment grade; and
    • mortgage and asset-backed securities and/or in index/structured securities. These financial instruments may be rated below investment grade.
  • Investing in any one of the above instruments may involve substantial credit/counterparty, market, liquidity, currency, leverage, index, interest and swap risks. If the issuers default, or such securities or their underlying assets, cannot be realised or perform badly, investors’ entire investments may be lost.
  • The Fund's investments involve developing markets. Owing to its potentially higher volatility and risk levels, as well as lower political and economic stability than developed markets, asset values could be affected in various levels.
  • The Fund’s investments may be more concentrated in terms of industry risk than others that diversify across industries and may therefore be subject to higher industry risk than funds with more diversified holdings.
  • The investment decision is yours. If you are in any doubt about the contents of this document, you should seek independent professional financial advice.
  • Investors should not only base on this document alone to make investment decisions and should read the Prospectus including the risk factors for further details.

Specific risks

Risk rating

Share

Invest in the power of disruption

Powerful themes are shaping, and being shaped by, disruption.

Click to read our investment managers’ insights.



Related funds

Classifications

Important message